Amocal

Quick links to important sections

Amocal

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amocal

What is Amocal? Definition, Class, and Purpose

Property Description
Active ingredient Amlodipine Besilate
Form Tablet (for oral use)
Pharmacological class Dihydropyridine Calcium Channel Blocker (CCB)
Common use Management of high blood pressure and chest pain (angina)
Origin Synthetic small molecule

Amocal is a prescription-only cardiovascular medicine whose active ingredient is Amlodipine Besilate, classified as a long-acting agent for managing vascular conditions. It is provided for oral administration in the pharmaceutical preparation of a tablet. The substance Amlodipine is a synthetic small molecule, developed as a single-ingredient product, or monotherapy, for therapeutic use. This characteristic makes it distinct from combination therapies, allowing for precise control of a specific pharmacological action.


Amocal's Pharmacological Class and General Purpose

Amocal belongs to the major drug class known as Calcium Channel Blockers (CCBs), specifically within the dihydropyridine subclass. Amlodipine is utilized for treating high blood pressure and preventing chest pain, reflecting its established role in clinical practice.

This pharmacological profile identifies Amocal as an Antihypertensive Agent and an Antianginal Agent. The general therapeutic purpose of this medicine type is to manage cardiovascular disorders by facilitating easier blood flow throughout the body. For instance, it is typically used for the sustained control of chronically elevated blood pressure, which is clinically recognized as a factor in maintaining long-term cardiac health.


Understanding the Dihydropyridine CCB Type

The dihydropyridine designation signifies that Amlodipine's action is primarily directed toward inducing vasodilation, or the widening of the peripheral arteries. Its chemical structure is designed to achieve this effect through the inhibition of calcium ion influx into the arterial smooth muscle cells, preventing their constriction.

Amlodipine's action is selective for the peripheral vascular system, distinguishing it from older generation CCBs. It is a commonly prescribed oral medication for controlling blood pressure and stable angina in adults. This targeted physiological effect defines its role in the pharmacological management of specific cardiovascular conditions.

Regulatory References

  1. NIH MedlinePlus: Amlodipine

What side effects are possible with Amocal?

Possible Side Effects and Safety Information

The official safety profile for Amocal (Amlodipine Besilate) is structured by regulatory authorities based on the frequency and physiological system affected by adverse reactions. This classification defines the drug's formally documented risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized from Common to Very Rare, reflecting data from clinical use. Common effects, reported in up to 1 in 10 patients, often include somnolence, dizziness, headache (especially at the beginning of treatment), flushing, abdominal pain, nausea, fatigue, and oedema (swelling, particularly ankle swelling), which is often noted as dose-dependent. Uncommon effects include insomnia, mood changes, tremor, syncope, and hypotension. Rare and Very Rare classifications cover a wide range of documented reactions.

Serious Adverse Reactions and Systemic Effects

Regulatory documents list certain rare events as serious. These Very Rare reactions include myocardial infarction, pancreatitis, hepatitis, and severe cutaneous reactions such as Erythema Multiforme and Stevens-Johnson syndrome. Reactions are categorized by System-Organ Classes, affecting the Nervous system, Vascular system, Cardiac system, Gastrointestinal system, and Skin, among others.

Safety Considerations and Restrictions

Specific safety considerations are noted for certain populations. A cautious, lower starting dose may be advised for older adults and patients with hepatic impairment, as reduced drug clearance may occur. The medication is formally contraindicated in patients with known sensitivity to dihydropyridine derivatives, severe hypotension, shock (including cardiogenic shock), and conditions like high-grade aortic stenosis that cause obstruction of the outflow tract of the left ventricle.

Overdose and Emergency Response

Overdose and When to Seek Help

Official Regulatory Information for Amocal Overdose

Overdose with Amocal (Amlodipine) is a serious medical emergency and requires immediate attention. Taking too much of the medication can lead to significant and potentially prolonged effects on the body's systems, particularly the cardiovascular system.

Documented Overdose Symptoms

The primary clinical manifestations of an overdose, as described in regulatory documents, include signs of severe circulatory distress:

  • Low Blood Pressure (Hypotension): A potentially dangerous drop in blood pressure.
  • Rapid Heartbeat (Tachycardia): A heart rate that is faster than normal.

Overdose risk is associated with doses that are significantly higher than the therapeutic range. The prolonged half-life of the active substance means that the onset of severe effects may be delayed, and the resulting low blood pressure can be sustained for a long duration.

Emergency Action Statement

Immediate medical help must be sought right away for any suspected overdose. Even if a person has taken too much Amocal and is currently showing no symptoms, they or their caregiver should contact a healthcare professional, hospital emergency department, or Poison Control Centre immediately for urgent guidance and treatment. Do not attempt to induce vomiting unless specifically instructed to do so by a medical authority.

Therapeutic Uses of Amocal

What Amocal Treats: Main Uses and Benefits

Amocal is considered relevant for use across several important therapeutic areas of cardiovascular health. The medication is applied in addressing high blood pressure and specific types of chest pain. It is generally relevant when supportive symptom management is appropriate for chronic conditions.

The medicine is commonly used to help with sustained control of hypertension, the management of angina episodes and chest pain, and providing long-term support for documented Coronary Artery Disease (CAD). Amocal may be part of symptomatic management in situations where patients experience periodic symptoms related to functional stress.

Sustained Management of Chronic Conditions

Amocal is generally applied as a foundational therapy for the sustained control of chronically elevated blood pressure in adults and may be considered for pediatric patients. This treatment assists with maintaining functional stability and supports general well-being in conditions marked by increased physiological stress. Furthermore, for those with angina, the use of Amocal plays a role in managing symptoms that become more disruptive during flare-ups, which supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.


Quick Fact: Support for Symptoms that Create Noticeable Physiological Strain

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Amocal

This section outlines the regulatory guidelines for who is eligible and who is prohibited from using Amocal (amoxicillin and clavulanate potassium) based on official governmental documentation.


Contraindicated Populations

Amocal is strictly contraindicated and must not be used by patients who have:

  • A history of a serious hypersensitivity reaction (such as anaphylaxis or Stevens-Johnson syndrome) to Amoxicillin/Clavulanate Potassium, other penicillins, or other beta-lactam antibiotics (e.g., cephalosporins).
  • A previous history of cholestatic jaundice or hepatic dysfunction that was associated with the use of Amoxicillin/Clavulanate Potassium.

Restricted or Special Consideration Groups

Special consideration or restrictions apply to the following groups:

  • Severe Renal Impairment: Patients with severe kidney impairment (creatinine clearance <30 mL/min) should not use the extended-release tablet formulation, and dosage adjustment is required for other forms.
  • Mononucleosis: The medication should be avoided in patients with suspected or confirmed infectious mononucleosis, as use is strongly associated with the development of a skin rash.
  • Pediatric Use: Certain tablet formulations are not recommended for children weighing less than 40 kg.

Safety summaries also advise caution when prescribing to patients with existing liver or kidney impairment, or those who are pregnant or nursing, though these are not formal contraindications in the core eligibility sections.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amocal (Amlodipine Besilate) has officially documented interaction patterns that are classified primarily based on pharmacokinetic and pharmacodynamic effects, as detailed in regulatory labeling.

Drug–Drug and Substance Interactions

Co-administered Substance/Class Formal Interaction Outcome Regulatory Constraint
CYP3A Inhibitors (Strong/Moderate) Co-administration results in an increase in the systemic exposure of Amocal. Use with caution due to altered clearance.
Simvastatin Amocal co-administration results in an increased exposure of Simvastatin. Simvastatin dose must not exceed 20 mg daily upon co-administration.
Cyclosporine / Tacrolimus Amocal co-administration leads to an increased exposure of the co-administered agent. Use with caution due to altered clearance.
CYP3A Inducers (e.g., St. John's Wort) May result in a reduction in the plasma concentrations of Amocal. Use with caution due to potential decreased exposure.
Other Antihypertensives Provides an additive blood pressure lowering effect. Pharmacodynamic reinforcement.

Food and Population-Specific Interactions

The general presence of food does not alter the bioavailability of Amocal. However, regulatory documents note that Amocal clearance is reduced in patients with hepatic impairment, which is associated with an increase in the overall systemic exposure of the medicine itself. No drug-drug combinations are explicitly labeled as contraindicated in the official regulatory documents for Amocal monotherapy.

Mechanism of Action

How Amocal Works

The mechanism of Amocal (Amlodipine) is defined by the selective modulation of calcium ion flow, which regulates the contractile state of vascular smooth muscle.

Selective Blockade of Vascular Calcium Channels

The action begins at the molecular level with the inhibition of L-type voltage-dependent calcium channels (Cav1.2) found primarily on arterial smooth muscle cells. By binding to a specific site on these channels, Amocal limits the transmembrane influx of calcium ions (Ca^2+), thereby interrupting the calcium signal necessary for subsequent muscle contraction.


Modulation of Systemic Vascular Resistance

The cellular blockade of calcium entry disrupts the excitation-contraction coupling pathway, causing the blood vessel walls to relax (vasodilation). This widening of peripheral arterioles is a functional consequence that significantly reduces the overall Systemic Vascular Resistance (SVR), leading to a decreased ventricular Afterload.


Favorable Myocardial Oxygen Balance

The same vasodilatory mechanism extends to the coronary arteries that supply the heart, increasing the delivery of oxygenated blood to the heart muscle. This action, combined with the decreased effort required of the heart due to reduced SVR, contributes to an improved ratio of myocardial oxygen supply to demand.

Dosage and Administration Information

How to Use Amocal: Administration Guidelines

Amocal (Amlodipine Besilate) is administered following a structured set of instructions focusing strictly on the mechanics of use rather than therapeutic benefits or safety.

Administration Scope

Instruction Detail
Route of Administration Amocal is administered orally as a tablet.
Dosing Schedule (Adults) The typical maintenance dose for both hypertension and angina is 5 mg to 10 mg once daily, with the maximum recommended dose being 10 mg once daily.
Dosing Schedule (Pediatric) For hypertension in patients aged 6–17 years, the recommended dose is 2.5 mg to 5 mg once daily.
Timing in Relation to Meals May be taken with or without food, as its absorption is not affected by meal intake.

Procedural Administration Rules

Instruction Detail
Frequency Pattern The medication is intended for once daily use and should be taken at approximately the same time each day.
Titration Interval Dosage adjustments, if required, should be performed over a 7- to 14-day interval to allow the body to reach a stable state.
Population-Specific Rules A lower starting dose of 2.5 mg once daily may be appropriate for older adults and patients with hepatic impairment. No adjustment is required for renal impairment.
Missed Dose Rule If a dose is missed, it should be taken as soon as the patient remembers on that day. If a full day has passed, the missed dose should be skipped, and the dose must not be doubled.
Special Restriction Consumption of grapefruit or grapefruit juice should be avoided.

Connection to the Overall Use Protocol

These instructions establish a standardized, long-term, once-daily oral administration protocol. The rules define precise dose ranges and maximum limits, govern the necessary time intervals between dose changes, and provide explicit guidelines for pediatric use, older adults, and handling a missed dose.

Recent Clinical Evidence

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research relies on large, randomized controlled trials (RCTs) comparing the medication against placebo or other study medications. Researchers monitored changes in blood pressure and tracked the occurrence of major cardiovascular events over long periods. While findings describe patterns observed in blood pressure control, the long-term patterns for cardiovascular events were observed across different study medications in some large comparative trials.

Evidence for Use in Managing Chronic Stable Angina and Vasospastic Angina

Amocal was studied for symptomatic treatment in conditions characterized by fluctuating symptoms, such as chronic stable angina and vasospastic angina. Controlled trials examined the change in outcomes related to physical discomfort (frequency of attacks) and the measured duration of activity level before symptoms were noted. Data for long-term cardiovascular event outcomes remain limited in this population, as most research is relevant in trials assessing short-term or episodic symptom patterns.

Evidence from Trials in Patients with Documented Coronary Artery Disease (CAD)

Research was evaluated in specific adult populations with angiographically documented CAD. Researchers tracked the occurrence of hospitalization due to acute episodes and the number of subjects receiving coronary revascularization procedures. When research examined the prevention of outcomes like non-fatal heart attack or all-cause mortality, findings were mixed or neutral in certain outcome trials compared to placebo. The results apply only to the populations studied.

Long-Term Studies and Durability of Evidence

Research was designed to explore outcomes related to systemic or functional imbalance like stroke occurrence over multi-year periods. The long-term data describe patterns related to cardiovascular event occurrence when compared with other drug classes. Evidence quality varies across studies for certain other long-term outcomes, such as hospitalization for heart failure.

Research in Special Populations and Comorbid Conditions

Research was evaluated in specific groups, including older adults and pediatric patients (ages 6 to 17 years) with high blood pressure, as well as patients with co-existing conditions like diabetes mellitus. Data for pediatric patients younger than 6 years old remain insufficient, as studies are not well characterized.

Understanding Evidence Gaps and Areas of Scientific Uncertainty

Comparative evidence is lacking for all possible long-term outcomes against every other available medication. Furthermore, long-term effects are not fully established for all endpoints in all subgroups. The research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Amocal (FAQ)

Q: Is Amocal the same type of medicine as [similar drug name]?

Amocal is officially classified as a dihydropyridine calcium channel blocker (CCB). Regulatory documents describe its specific mechanism as primarily targeting the arteries to limit the flow of calcium ions, which helps the blood vessels relax. This specific pharmacological class describes its functional characteristics as defined in regulatory documents.


Q: How quickly do people typically start to feel the effects of Amocal?

Official information indicates that the drug’s action is gradual. It typically takes about 6 to 12 hours after taking a dose for the active substance to reach its peak level in the blood. Regulatory sources describe that the body reaches stable drug levels (steady-state) after approximately 7 to 8 days of consecutive daily dosing.


Q: Is it common to feel tired when starting Amocal?

Regulatory documents list both fatigue and somnolence (sleepiness) as adverse reactions that are classified as common. Official product information often notes that common effects like headache can be particularly noticeable when treatment begins.


Q: Does Amocal cause weight gain or loss?

Official safety documents include both weight gain and weight decrease among the reported adverse reactions observed during clinical use. However, regulatory sources classify these specific events as uncommon in the overall safety profile of the medicine.


Q: Is Amocal safe for use in older adults (seniors)?

Official guidelines describe that a lower dose may be considered for this population due to reduced drug clearance. This reduced clearance is noted in regulatory information for older adults.


Q: Can I take Amocal if I have a history of kidney problems?

Official administration rules state that for patients with existing renal impairment (kidney problems), an initial adjustment to the dosage is typically not required. Clearance is not significantly affected by renal impairment.


Q: How is Amocal handled by the liver?

Amocal is primarily processed and converted into inactive substances by the liver. Regulatory documents note that if a person has existing hepatic impairment (liver problems), this process may be slowed, leading to increased exposure of the drug in the body.


Q: Why do some people report feeling no difference when taking Amocal?

Official documents explain that because the drug treats conditions, such as high blood pressure, that may not have obvious symptoms, patients may not perceive a change when the medicine is functioning as described. The onset of therapeutic effect is characterized as gradual.


Q: Is Amocal safe for long-term use?

Regulatory information describes its indication for the sustained or long-term management of chronic conditions. The antihypertensive effectiveness of Amocal is documented as being maintained over time with continued daily administration.


Q: Is Amocal available without a prescription?

According to regulatory and official health information sources, Amocal is designated as a prescription-only medication.


Q: Is Amocal used for things other than its main purpose?

Regulatory documents explicitly define the approved uses as the treatment of hypertension (high blood pressure) and specific types of angina (chest pain). Information provided in this FAQ is strictly limited to these approved indications.


Q: How long is Amocal usually prescribed for?

Amocal is primarily indicated for the treatment of chronic conditions like stable angina and hypertension. Regulatory information implies that its use is intended for long-term or sustained therapeutic control, rather than short-term periods.


Q: Are there long-term side effects associated with Amocal use?

The official safety profile provides a list of all adverse reactions reported from clinical trials and post-marketing experience, classifying them by frequency (e.g., Common, Uncommon, Very Rare). These documented effects cover the spectrum of use, including prolonged periods.


Q: Is it okay to drive a car while taking Amocal?

Regulatory documents advise that the ability to drive or operate machinery may be affected by reported adverse reactions, such as dizziness, headache, or fatigue, particularly at the start of treatment or following a dose change.


Q: Does Amocal help with sleep issues?

Official safety documents include insomnia (difficulty sleeping) among the reported adverse reactions, classifying it as an uncommon event. Amocal is not indicated for the treatment of sleep issues.


Q: Can men and women take Amocal for the same conditions?

The regulatory indications for Amocal for the treatment of hypertension and angina are defined for the adult population as a whole. The usage guidelines provided in official documents do not differentiate by sex for these conditions.


Q: What is the likelihood of a serious allergic reaction to Amocal?

Regulatory documents classify the occurrence of severe hypersensitivity reactions, such as angioedema (swelling beneath the skin) and severe skin reactions, as very rare events. These types of reactions are strictly documented in the official safety profile.


Q: Can Amocal affect mood or behavior?

Official safety documentation lists several adverse reactions related to the nervous system and psychiatric effects. These include reported events such as mood changes, nervousness, anxiety, depression, and abnormal dreams.


Q: Does the research on Amocal include studies in children?

Research was conducted in pediatric patients specifically between the ages of 6 and 17 years for the treatment of high blood pressure. Official documents indicate that the use in children younger than 6 years of age is not well characterized.


Q: What is the typical time frame for side effects to appear after starting Amocal?

Official regulatory information notes that certain common adverse reactions, such as headache and swelling, can be most prominent at the beginning of treatment. These effects are often documented to decrease in severity with continued use.


Q: Is it safe to travel across time zones while taking Amocal?

Official guidelines recommend taking the medication once daily at approximately the same time each day to maintain consistent drug levels. This consistency is generally advised even when traveling across time zones.


Q: What is the average time it takes for Amocal to leave the body?

The time required for half of the drug to be eliminated from the body is known as the terminal elimination half-life. Official pharmacological data state this is approximately 30 to 50 hours in most adult patients.


Q: Are there specific symptoms that require immediate medical attention while on Amocal?

Official documents list Very Rare serious adverse reactions that would generally necessitate urgent medical evaluation. These include severe events such as myocardial infarction (heart attack), pancreatitis, and severe generalized allergic skin reactions.

How should Amocal be stored and disposed of?

How to Store and Dispose of Amocal?

Proper storage and disposal of Amocal are essential to maintain its efficacy and ensure safety. Store Amocal tablets in their original packaging at room temperature, away from direct sunlight, heat, and moisture. Do not store the medicine in the bathroom or near the kitchen sink. Always ensure that the medication is kept out of the reach and sight of children and pets in a secure location.

Never use Amocal past its expiration date. For disposal of unused or expired Amocal, do not flush it down the toilet or pour it down a drain unless specifically instructed to do so by a healthcare provider or drug disposal program. The preferred method for safe disposal is through a drug take-back program or by finding a DEA-authorized collector site in your community, which is often available at local pharmacies or police stations. If a take-back option is not available and the medicine is not on a designated flush list, dispose of it in the household trash after mixing it with an undesirable substance (like coffee grounds or kitty litter) and sealing it in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amocal found in:

A-Z Index: